T. Y. Oliveira

This study compares memory B cell responses after Delta and Omicron BA.1 breakthrough infections versus mRNA vaccine doses, finding that Delta infection boosts overall memory B cell potency and breadth, while Omicron infection only enhances strain-specific responses.

This study compares humoral immune responses to different SARS-CoV-2 vaccination regimens, finding differences in antibody and memory B cell responses and neutralizing breadth against variants.

This study compares memory B cell responses after single-dose Ad26.COV2.S and mRNA vaccines, finding lower quantities but comparable neutralizing quality in Ad26.COV2.S recipients.

This study shows that a third mRNA vaccine dose increases the potency and breadth of SARS-CoV-2 neutralizing antibodies, particularly against the Omicron variant, through the expansion and evolution of memory B cells.

The paper identifies conserved neutralizing epitopes on the N-terminal domain of SARS-CoV-2 spike proteins using NTD-specific probes and characterizes antibodies that neutralize multiple variants.

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

The paper shows that SARS-CoV-2 infection leads to persistent, functional memory T cell responses and enduring immune alterations in CD4+ and CD8+ T cells six months post-infection.

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

This paper reports a broadly neutralizing monoclonal antibody from a macaque infected with SHIVAD8 that targets the V3-glycan patch of HIV-1 Env, showing neutralizing activity and protective efficacy in vivo.